TABLE 4:
Univariate correlations between MR imaging measures of MS activity and burden of disease
| Variable 1* | Variable 2* | All Patients (n = 239) | Placebo Group (n = 120) | GA Group (n = 119) |
|---|---|---|---|---|
| Baseline T2 LV | On-trial EL | 0.51 (<.001) | 0.55 (<.001) | 0.47 (<.001) |
| Baseline T2 LV | On-trial new T2 lesions | 0.32 (<.001) | 0.40 (<.001) | 0.24 (.009) |
| Baseline T2 LV | T2 DLV | 0.37 (<.001) | 0.44 (<.001) | 0.30 (.001) |
| Baseline T2 LV | T1 DLV | 0.50 (<.001) | 0.48 (<.001) | 0.53 (<.0001) |
| Baseline T1 LV | On-trial EL | 0.36 (<.001) | 0.41 (<.001) | 0.29 (.001) |
| Baseline T1 LV | On-trial new T2 lesions | 0.19 (.003) | 0.28 (.002) | 0.10 |
| Baseline T1 LV | T1 DLV | 0.29 (<.001) | 0.33 (<.001) | 0.24 (.009) |
| Baseline T1 LV | T2 DLV | 0.17 (.007) | 0.22 (0.02) | 0.13 |
Note.—Values are the Spearman rank correlation coefficients. Data in parentheses are P values ≤.05.
*
DLV indicates the difference in lesion volume between month 9 images and baseline images; LV, lesion volume; on-trial EL, the total number of Gd-enhancing lesions during the 9 months of the study.